BACKGROUND: Plasmodium vivax (p. vivax) malaria was traditionally considered as benign tertian malaria, however, recent studies have pointed out that p. vivax have potential to cause all severe complications previously attributed to p. falciparum infection only. The aim of this report is to study the incidence of various clinical and biochemical complications associated with severe p. vivax malaria. METHODS: A retrospective analysis was performed on all patients with p. vivax malaria admitted to our center between January 2009 and December 2011. Severe malaria was defined as per World Health Organization (WHO) criteria. Clinical and laboratory parameters were recorded. Patients with evidence of p. falciparum, mixed malarial infection and chronic systemic diseases were excluded from the study. RESULTS: Sixty-two patients met the criteria for severe malaria during the study period. The complications observed were Hepatic dysfunction in 18 (29%), renal dysfunction in 13 (21%), cerebral malaria in 10 (16.1%), acute respiratory distress syndrome (ARDS) in 6 (9.7%), shock in 10 (16.1%), severe anemia in 16 (25.8%), thrombocytopenia in 35 (56.5%), and hypoglycemia in 3 (4.8%) patients. Three mortalities were observed. CONCLUSIONS: P. vivax has immense potential to cause life threatening complications and even death, more research is required to understand the exact pathogenesis of various complications encountered in vivax malaria.
BACKGROUND:Plasmodium vivax (p. vivax) malaria was traditionally considered as benign tertian malaria, however, recent studies have pointed out that p. vivax have potential to cause all severe complications previously attributed to p. falciparum infection only. The aim of this report is to study the incidence of various clinical and biochemical complications associated with severe p. vivaxmalaria. METHODS: A retrospective analysis was performed on all patients with p. vivaxmalaria admitted to our center between January 2009 and December 2011. Severe malaria was defined as per World Health Organization (WHO) criteria. Clinical and laboratory parameters were recorded. Patients with evidence of p. falciparum, mixed malarial infection and chronic systemic diseases were excluded from the study. RESULTS: Sixty-two patients met the criteria for severe malaria during the study period. The complications observed were Hepatic dysfunction in 18 (29%), renal dysfunction in 13 (21%), cerebral malaria in 10 (16.1%), acute respiratory distress syndrome (ARDS) in 6 (9.7%), shock in 10 (16.1%), severe anemia in 16 (25.8%), thrombocytopenia in 35 (56.5%), and hypoglycemia in 3 (4.8%) patients. Three mortalities were observed. CONCLUSIONS:P. vivax has immense potential to cause life threatening complications and even death, more research is required to understand the exact pathogenesis of various complications encountered in vivax malaria.
Authors: Fernando Val; Kim Machado; Lisiane Barbosa; Jorge Luis Salinas; André Machado Siqueira; Maria Graças Costa Alecrim; Hernando Del Portillo; Quique Bassat; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Antonio C Martins; Jamille B Lins; Luana M N Santos; Licia N Fernandes; Rosely S Malafronte; Teresa C Maia; Melissa C V Ribera; Ricardo B Ribera; Monica da Silva-Nunes Journal: Malar J Date: 2014-02-18 Impact factor: 2.979
Authors: Fábio A Leal-Santos; Soraya B R Silva; Natasha P Crepaldi; Andréia F Nery; Thamires O G Martin; Eduardo R Alves-Junior; Cor J F Fontes Journal: Malar J Date: 2013-12-27 Impact factor: 2.979